AveXis (NASDAQ:AVXS) issued its quarterly earnings results on Tuesday. The company reported ($2.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.91), Bloomberg Earnings reports.
Shares of AveXis (AVXS) traded down $0.50 during mid-day trading on Wednesday, hitting $123.27. 376,200 shares of the stock were exchanged, compared to its average volume of 575,623. AveXis has a 52-week low of $61.43 and a 52-week high of $128.00. The company has a market capitalization of $4,515.40, a price-to-earnings ratio of -22.09 and a beta of 2.10.
A number of research analysts recently issued reports on the stock. Royal Bank of Canada reissued a “hold” rating and set a $92.00 price target on shares of AveXis in a research report on Thursday, November 2nd. BidaskClub upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Sanford C. Bernstein restated an “outperform” rating and set a $144.00 price objective (up from $110.00) on shares of AveXis in a research note on Tuesday, February 20th. Chardan Capital restated a “buy” rating and set a $135.00 price objective on shares of AveXis in a research note on Friday, January 5th. Finally, UBS Group set a $122.00 price objective on shares of AveXis and gave the company a “buy” rating in a research note on Friday, January 5th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and sixteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $122.40.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3228012/avexis-avxs-announces-earnings-results-misses-estimates-by-0-91-eps.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.